Show simple item record

AuthorAllouch S.
AuthorMunusamy S.
Available date2020-03-29T12:12:12Z
Publication Date2018
Publication NameCurrent Drug Targets
ResourceScopus
ISSN13894501
URIhttp://dx.doi.org/10.2174/1389450118666170601130947
URIhttp://hdl.handle.net/10576/13535
AbstractBackground: Chronic kidney disease (CKD) is a condition increasingly affecting millions of individuals worldwide and is ranked as the ninth leading cause of death in the United States. AMP-activated protein kinase (AMPK) is an energy sensor that plays a pivotal role in cellular homoeostasis. Deficiency in AMPK activity and autophagic signaling, and sustained activation of mammalian target of rapamycin (mTOR) signaling and endoplasmic reticulum (ER) stress have been shown to promote epithelial-to-mesenchymal transition (EMT) and renal cell apoptosis and contribute to CKD. Emerging evidences demonstrate that AMPK acts as a modulator of the aforementioned pathways that underpin the pathophysiology of CKD. Furthermore, pharmacological activators of AMPK such as metformin have been shown to exert renoprotective effects in experimental studies and improve clinical outcomes in patients with CKD. Objective: The current review focuses on the nephroprotective effects of AMPK and its utility as a therapeutic target for the prevention and treatment of CKD.
Languageen
PublisherBentham Science Publishers B.V.
SubjectAMP-activated protein kinase
Apoptosis
Autophagy
Chronic kidney disease
Endoplasmic reticulum stress
Epithelial-mesenchymal transition
Mammalian target of rapamycin
Metformin
TitleAMP-activated protein kinase as a drug target in chronic kidney disease
TypeArticle Review
Pagination709-720
Issue Number6
Volume Number19
dc.accessType Abstract Only


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record